HIV-1 Vaccines and Adaptive Trial Designs

See allHide authors and affiliations

Science Translational Medicine  20 Apr 2011:
Vol. 3, Issue 79, pp. 79ps13
DOI: 10.1126/scitranslmed.3001863


Developing a vaccine against the human immunodeficiency virus (HIV) poses an exceptional challenge. There are no documented cases of immune-mediated clearance of HIV from an infected individual, and no known correlates of immune protection. Although nonhuman primate models of lentivirus infection have provided valuable data about HIV pathogenesis, such models do not predict HIV vaccine efficacy in humans. The combined lack of a predictive animal model and undefined biomarkers of immune protection against HIV necessitate that vaccines to this pathogen be tested directly in clinical trials. Adaptive clinical trial designs can accelerate vaccine development by rapidly screening out poor vaccines while extending the evaluation of efficacious ones, improving the characterization of promising vaccine candidates and the identification of correlates of immune protection.


  • Citation: L. Corey, G. J. Nabel, C. Dieffenbach, P. Gilbert, B. F. Haynes, M. Johnston, J. Kublin, H. C. Lane, G. Pantaleo, L. J. Picker, A. S. Fauci, HIV-1 Vaccines and Adaptive Trial Designs. Sci. Transl. Med. 3, 79ps13 (2011).

View Full Text

Stay Connected to Science Translational Medicine